Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2017
Pharmacy Choice - Pharmaceutical News - PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Other Events - April 24, 2017

Pharmacy News Article

 4/18/17 - PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Other Events

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Other Events

Item8.01.

Other Events.

The recently reconstituted Compensation Committee, comprised of
Bruce Horowitz, Dominic Rodrigues and Jan Koe (the
Compensation Committee), of the Board of Directors (the
Board) of Provectus Biopharmaceuticals, Inc. (the
Company) met on April12, 2017 to review and analyze the
existing compensation of the Board and the various Board
committees established in June 2016. At this meeting, the
Compensation Committee unanimously adopted the following policies
and practices regarding director (Director) compensation
for 2017, which were also approved by the Board by unanimous
written consent, effective April14, 2017:

Board, Committee, and committee chairperson
retainers:

Non-employee Directors will continue to be paid $40,000 per
year for service on the Board.
Directors serving on the Corporate Governance and Nominating
Committee will continue to be paid $10,000 per year; the
chairperson of the Corporate Governance and Nominating
Committee will continue to be paid $15,000 per year.

Modified committee and committee chairperson
retainers:

Compensation for Directors serving on the Audit Committee
will be decreased from $20,000 per year to $15,000 per year;
the Audit Committee Chairpersons compensation will be
decreased from $25,000 per year to $15,000 per year.
Compensation for Directors serving on the Compensation
Committee will be decreased from $15,000 per year to $10,000
per year; the Compensation Committee Chairpersons
compensation will be decreased from $20,000 per year to
$15,000 per year.
The Board (rather than a search committee) will oversee the
Companys search for a Chief Medical Officer, a new Chief
Executive Officer, and other executive management positions,
as appropriate; however, there will be no additional
compensation paid to the Directors for their work during this
executive management search.

Other modifications:

Neither stock option grants to purchase shares of the
Companys common stock nor shares of restricted common stock
were awarded to non-employee Directors.
There will be no additional compensation for serving as
Chairperson of the Board or Lead Independent Director.
Director fees will be paid on a monthly, pro-rated basis;
provided, however, these fees will accrue until such time as
the Board approves the payment of Director compensation.

Committee chairpersons:

Bruce Horowitz assumed the role of Chairpersonship of the
Corporate Governance and Nominating Committee.
Dominic Rodrigues assumed the role of Chairperson of the
Audit Committee.
Jan E. Koe remains as the Chairperson of the Compensation
Committee.

Director compensation for 2016 and
2017:

Director fees for 2016 earned or paid in cash to non-employee
Directors ranged from $90,000 to $130,000.
Director fees for 2017 are projected to be approximately
$75,000 per Director, which results in a year-over-year
decrease of approximately 17% to 42%.

2

About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors. PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information
PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session down -0.0005 at 0.0405 with 660,982 shares trading hands.

The post PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Other Events appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Apr 25: Skin Infections: Focus on Cellulitis & MRSA
Last Chance
Apr 26: Medical Marijuana: Examining the Science, Not the Politics
Apr 27: What's New? New Treatments for Type 2 Diabetes
Apr 30: Using Effective Communication to Reduce Medication Errors
May 01: The New Hypertension Guidelines: What are They Telling Us?
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415